A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India.

AZD1222 COVID-19 Immunogenicity SII-ChAdOx1 nCoV-19 Safety

Journal

EClinicalMedicine

ISSN: 2589-5370

Titre abrégé: EClinicalMedicine

Pays: England

ID NLM: 101733727

Informations de publication

Date de publication:
Dec 2021

Historique:

received: 19 08 2021

revised: 29 10 2021

accepted: 11 11 2021

pubmed: 7 12 2021

medline: 7 12 2021

entrez: 6 12 2021

Statut: ppublish

Résumé

This phase 2/3 immunobridging study evaluated the safety and immunogenicity of the ChAdOx1 nCoV-19 Coronavirus Vaccine (Recombinant) (SII-ChAdOx1 nCoV-19), manufactured in India at the Serum Institute of India Pvt Ltd (SIIPL), following technology transfer from the AstraZeneca. This participant-blind, observer-blind study randomised participants 3:1 to SII-ChAdOx1 nCoV-19 or AZD1222 (ChAdOx1 nCoV-19) (immunogenicity/reactogenicity cohort) and 3:1 to SII-ChAdOx1 nCoV-19 or placebo (safety cohort). The study participants were enrolled from 14 hospitals across India between August 25 and October 31, 2020. Two doses of study products were given 4 weeks apart. The primary objectives were to demonstrate non-inferiority of SII-ChAdOx1 nCoV-19 to AZD1222 in terms of geometric mean titre (GMT) ratio of anti-SARS-CoV-2 spike IgG antibodies 28 days after the second dose (defined as lower limit of 95% CI >0·67) and to determine the incidence of serious adverse events (SAEs) causally related to SII-ChAdOx1 nCoV-19. The anti-spike IgG response was assessed using a multiplexed electrochemiluminescence-based immunoassay. Safety follow-up continued until 6 months after first dose. Trial registration: CTRI/2020/08/027170. 1601 participants were enrolled: 401 to the immunogenicity/reactogenicity cohort and 1200 to the safety cohort. After two doses, seroconversion rates for anti-spike IgG antibodies were more than 98·0% in both the groups. SII-ChAdOx1 nCoV-19 was non-inferior to AZD1222 (GMT ratio 0·98; 95% CI 0·78-1·23). SAEs were reported in ≤ 2·0% participants across the three groups; none were causally related. A total of 34 SARS-CoV-2 infections were reported; of which 6 occurred more than 2 weeks after the second dose; none were severe. SII-ChAdOx1 nCoV-19 has a non-inferior immune response compared to AZD1222 and an acceptable safety/reactogenicity profile. Pharmacovigilance should be maintained to detect any safety signals. SIIPL funded the contract research organisation and laboratory costs, while the site costs were funded by the Indian Council of Medical Research. The study vaccines were supplied by SIIPL and AstraZeneca.

Sections du résumé

BACKGROUND BACKGROUND

METHODS METHODS

This participant-blind, observer-blind study randomised participants 3:1 to SII-ChAdOx1 nCoV-19 or AZD1222 (ChAdOx1 nCoV-19) (immunogenicity/reactogenicity cohort) and 3:1 to SII-ChAdOx1 nCoV-19 or placebo (safety cohort). The study participants were enrolled from 14 hospitals across India between August 25 and October 31, 2020. Two doses of study products were given 4 weeks apart. The primary objectives were to demonstrate non-inferiority of SII-ChAdOx1 nCoV-19 to AZD1222 in terms of geometric mean titre (GMT) ratio of anti-SARS-CoV-2 spike IgG antibodies 28 days after the second dose (defined as lower limit of 95% CI >0·67) and to determine the incidence of serious adverse events (SAEs) causally related to SII-ChAdOx1 nCoV-19. The anti-spike IgG response was assessed using a multiplexed electrochemiluminescence-based immunoassay. Safety follow-up continued until 6 months after first dose. Trial registration: CTRI/2020/08/027170.

FINDINGS RESULTS

1601 participants were enrolled: 401 to the immunogenicity/reactogenicity cohort and 1200 to the safety cohort. After two doses, seroconversion rates for anti-spike IgG antibodies were more than 98·0% in both the groups. SII-ChAdOx1 nCoV-19 was non-inferior to AZD1222 (GMT ratio 0·98; 95% CI 0·78-1·23). SAEs were reported in ≤ 2·0% participants across the three groups; none were causally related. A total of 34 SARS-CoV-2 infections were reported; of which 6 occurred more than 2 weeks after the second dose; none were severe.

INTERPRETATION CONCLUSIONS

SII-ChAdOx1 nCoV-19 has a non-inferior immune response compared to AZD1222 and an acceptable safety/reactogenicity profile. Pharmacovigilance should be maintained to detect any safety signals.

FUNDING BACKGROUND

SIIPL funded the contract research organisation and laboratory costs, while the site costs were funded by the Indian Council of Medical Research. The study vaccines were supplied by SIIPL and AstraZeneca.

Identifiants

DOI: 10.1016/j.eclinm.2021.101218 PMID: 34870133 PMC: PMC8629682

pubmed: 34870133

doi: 10.1016/j.eclinm.2021.101218

pii: S2589-5370(21)00499-5

pmc: PMC8629682

doi:

Types de publication

Journal Article

Langues

eng

Pagination

101218

Informations de copyright

Déclaration de conflit d'intérêts

PSK, CB, AD, MG, US, DK, and BG are employees of SIIPL. JV and EJK are employees of AstraZeneca. All other authors declare no competing interests.

Références

Nat Med. 2021 Feb;27(2):270-278

pubmed: 33335323

Lancet. 2021 Jan 9;397(10269):99-111

pubmed: 33306989

Nat Commun. 2021 May 11;12(1):2670

pubmed: 33976165

NPJ Vaccines. 2021 Feb 22;6(1):28

pubmed: 33619260

Nat Med. 2021 Feb;27(2):279-288

pubmed: 33335322

Mayo Clin Proc. 2021 Sep;96(9):2493-2494

pubmed: 34366135

Eur J Intern Med. 2021 Nov;93:112-113

pubmed: 34419309

Lancet. 2021 Dec 19;396(10267):1979-1993

pubmed: 33220855

Lancet. 2021 Mar 6;397(10277):881-891

pubmed: 33617777

EClinicalMedicine. 2021 Jul 23;38:101038

pubmed: 34505032

N Engl J Med. 2021 May 20;384(20):1885-1898

pubmed: 33725432

Lancet. 2020 Aug 15;396(10249):467-478

pubmed: 32702298

J Med Virol. 2022 Jan;94(1):407-412

pubmed: 34491572

Lancet Infect Dis. 2020 Aug;20(8):e192-e197

pubmed: 32539990

Lancet. 2021 Aug 14;398(10300):577-578

pubmed: 34329583